ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Cincinnati, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Cincinnati, OH, USA:

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Cincinnati, Ohio, United States and 166 other locations

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

vs placebo as adjuvant therapy in participants who have triple negative breast cancer (TNBC).After a screening ph...

Active, not recruiting
Triple Negative Breast Neoplasms
Biological: Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim
Drug: Cyclophosphamide

Phase 3

Merck Sharp & Dohme (MSD)
Merck Sharp & Dohme (MSD)

Cincinnati, Ohio, United States and 192 other locations

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Cincinnati, Ohio, United States and 288 other locations

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple...

Active, not recruiting
Metastatic Triple Negative Breast Cancer
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).

Phase 2

AstraZeneca
AstraZeneca

Cincinnati, Ohio, United States and 140 other locations

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC (CAPItello-290)

III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Capivasertib
Drug: Placebo

Phase 3

AstraZeneca
AstraZeneca

Cincinnati, Ohio, United States and 260 other locations

Study of JANX008 in Subjects with Advanced or Metastatic Solid Tumor Malignancies

pharmacokinetics (PK), pharmacodynamics (PD), and preliminary anti-tumor activity of JANX008 in adult subjects with advanced or metastatic c...

Enrolling
Small Cell Lung Cancer
Triple-negative Breast Cancer
Drug: JANX008

Phase 1

Janux Therapeutics

Cincinnati, Ohio, United States and 12 other locations

TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers

including metastatic colorectal cancer (mCRC) patients....

Enrolling
Cancer
Drug: cetuximab
Drug: FOLFIRI

Phase 1

Tizona Therapeutics

Cincinnati, Ohio, United States and 38 other locations

Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors

with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended d...

Enrolling
TNBC - Triple-Negative Breast Cancer
Castration-resistant Prostate Cancer
Biological: Keytruda® (pembrolizumab)
Biological: XmAb®808

Phase 1

Xencor
Xencor

Cincinnati, Ohio, United States and 11 other locations

CAB-ROR2-ADC Safety and Efficacy Study in Patients with TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors...

Active, not recruiting
Non Small Cell Lung Cancer
Head and Neck Cancer
Biological: PD-1 inhibitor
Biological: CAB-ROR2-ADC

Phase 1, Phase 2

BioAtla

Cincinnati, Ohio, United States and 58 other locations

A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer

This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers...

Enrolling
Squamous Non-small-cell Lung Cancer
Advanced Solid Tumor
Drug: VLS-1488

Phase 1, Phase 2

Volastra Therapeutics

Cincinatti, Ohio, United States and 10 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2024 Veeva Systems